These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 8442152)

  • 21. Incidence and risk factors for development of malignant neoplasia after feline renal transplantation and cyclosporine-based immunosuppression.
    Schmiedt CW; Grimes JA; Holzman G; McAnulty JF
    Vet Comp Oncol; 2009 Mar; 7(1):45-53. PubMed ID: 19222830
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunosuppression modifications and graft outcome in patients with chronic allograft nephropathy.
    El-Agroudy AE; El-Dahshan K; Mahmoud K; Ismail AM; El-Baz M; Shokeir AA; Ghoneim MA
    Exp Clin Transplant; 2008 Sep; 6(3):203-10. PubMed ID: 18954298
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Varicella-zoster infection in cyclosporine A-treated renal transplant patients.
    Lo CY; Cheng IK
    Transplant Proc; 1996 Jun; 28(3):1511-2. PubMed ID: 8658764
    [No Abstract]   [Full Text] [Related]  

  • 24. Kidney transplantation from living donors in Italy.
    Berloco P; Pretagostini R; Poli L; Colonnello M; Alfani D; Cortesini R
    Transplant Proc; 1996 Dec; 28(6):3593-6. PubMed ID: 8962391
    [No Abstract]   [Full Text] [Related]  

  • 25. Optimizing the use of cyclosporine (Neoral) for recipients of living donor kidneys.
    Vincenti F; Brennan TV; Fuller TF; Feng S
    Transplant Proc; 2004 Mar; 36(2 Suppl):50S-53S. PubMed ID: 15041306
    [No Abstract]   [Full Text] [Related]  

  • 26. Comparative results of second kidney transplantation.
    Velidedeoğlu E; Tokyay R; Cuhadaroğlu S; Haberal M
    Transplant Proc; 1992 Oct; 24(5):1846-7. PubMed ID: 1412877
    [No Abstract]   [Full Text] [Related]  

  • 27. Quantification of interstitial fibrosis by image analysis on routine renal biopsy 1 year after transplantation in patients managed by C2 monitoring of cyclosporine microemulsion.
    Servais A; Meas-Yedid V; Buchler M; Morelon E; Olivo-Marin JC; Thervet E
    Transplant Proc; 2007 Oct; 39(8):2560-2. PubMed ID: 17954173
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The natural history of renal function following orthotopic heart transplant.
    Al Aly Z; Abbas S; Moore E; Diallo O; Hauptman PJ; Bastani B
    Clin Transplant; 2005 Oct; 19(5):683-9. PubMed ID: 16146562
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumors after renal transplantation.
    Büyükpamukçu N; Karakayali H; Bilgin N
    Transplant Proc; 1996 Aug; 28(4):2317-8. PubMed ID: 8769235
    [No Abstract]   [Full Text] [Related]  

  • 30. Post-transplant de novo malignancies in renal transplant recipients: the past and present.
    Kauffman HM; Cherikh WS; McBride MA; Cheng Y; Hanto DW
    Transpl Int; 2006 Aug; 19(8):607-20. PubMed ID: 16827677
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cyclosporine increases endothelin-1 plasma levels in renal transplant recipients.
    Cauduro RL; Costa C; Lhulier F; Garcia RG; Cabral RD; Gonçalves LE; Manfro RC
    Transplant Proc; 2004 May; 36(4):880-1. PubMed ID: 15194301
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A long-term study on hyperlipidemia in stable renal transplant recipients.
    Tse KC; Lam MF; Yip PS; Li FK; Lai KN; Chan TM
    Clin Transplant; 2004 Jun; 18(3):274-80. PubMed ID: 15142048
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acute respiratory distress syndrome after kidney transplantation: epidemiology, risk factors, and outcomes.
    Shorr AF; Abbott KC; Agadoa LY
    Crit Care Med; 2003 May; 31(5):1325-30. PubMed ID: 12771598
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does acute tubular necrosis affect renal transplant outcome? The impact of rejection episodes.
    Troppmann C; Almond PS; Payne WD; Dunn DL; Gores PF; Gruessner RW; Sutherland DE; Matas AJ; Najarian JS
    Transplant Proc; 1993 Feb; 25(1 Pt 2):905. PubMed ID: 8442263
    [No Abstract]   [Full Text] [Related]  

  • 35. Neoquadruple induction with antithymocyte globulin/azathioprine/cyclosporine/prednisolone in simultaneous pancreas and kidney transplant recipients: 8.5-year results.
    Schulz T; Kapischke M; Busing M
    Transplant Proc; 2005 May; 37(4):1815-7. PubMed ID: 15919475
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sirolimus-based therapy with or without cyclosporine: long-term follow-up in renal transplant patients.
    Morales JM; Campistol JM; Kreis H; Mourad G; Eris J; Schena FP; Grinyo JM; Nanni G; Andres A; Castaing N; Brault Y; Burke JT
    Transplant Proc; 2005 Mar; 37(2):693-6. PubMed ID: 15848504
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Primary immunosuppression with tacrolimus in kidney transplantation: three-year follow-up in a single center.
    Kim HC; Hwang EA; Han SY; Park SB; Kim HT; Cho WH
    Transplant Proc; 2004 Sep; 36(7):2082-3. PubMed ID: 15518753
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Results of 1074 kidney transplants in Chile.
    Meléndez M; Elgueta S; Wegmann ME; Santamaría L; Fuentes C
    Transplant Proc; 1993 Jun; 25(3):2386-8. PubMed ID: 8516936
    [No Abstract]   [Full Text] [Related]  

  • 39. Clinical algorithms for cyclosporine management based on pathophysiologic constructs of nephrotoxicity.
    Bennett WM
    Transplant Proc; 1994 Oct; 26(5):2583-4. PubMed ID: 7940801
    [No Abstract]   [Full Text] [Related]  

  • 40. Cancer development in pediatric primary renal allograft recipients.
    Gruber SA; Gillingham K; Sothern RB; Stephanian E; Chavers B; Matas AJ; Dunn DL
    Transplant Proc; 1994 Feb; 26(1):3-4. PubMed ID: 8108991
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.